trending Market Intelligence /marketintelligence/en/news-insights/trending/9ty3e6GRk1BEpI_Mg0xbDQ2 content esgSubNav
In This List

US FDA approves Acorda's Parkinson's treatment

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms


US FDA approves Acorda's Parkinson's treatment

Ardsley, N.Y.-based Acorda Therapeutics Inc. said the U.S. Food and Drug Administration approved its Parkinson's treatment Inbrija.

Inbrija is a formulation of one of the main drugs used to treat Parkinson's — levodopa. It will be used in patients experiencing so-called off periods, when the effects of an existing medication start to wear off in between doses, or the re-emergence of Parkinson's symptoms.

Acorda's medicine will be commercially available during the first quarter of 2019.